Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors-Reference-Cited by-同舟云学术

Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors

Published:2024-04-24 Issue:9 Volume:67 Page:7197-7223
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Wang Junwei¹^ORCID,Rong Quanjin¹,Ye Lei¹,Fang Bingqian¹,Zhao Yifan¹,Sun Yu¹,Zhou Haikun¹,Wang Dan¹,He Jinting¹,Cui Zhenzhen¹,Zhang Qijian¹,Kang Di¹,Hu Lihong¹

Affiliation:

1. Jiangsu Key Laboratory for Functional Substance of Chinese Medicine, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, P. R. China

Funder

Graduate Research and Innovation Projects of Jiangsu Province

Natural Science Foundation of Jiangsu Province

Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions

National Natural Science Foundation of China

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c00051

Reference42 articles.

1. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

2. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm

3. Targeting FLT3 mutations in AML: review of current knowledge and evidence

4. Strategies targeting FLT3 beyond the kinase inhibitors

5. FLT3 inhibitors in acute myeloid leukemia

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives;European Journal of Medicinal Chemistry;2024-11